Table 3.
Comparison of biomarkers at baseline and after six months in active and inactive disease group.
| Activity at baseline |
Activity at six months |
||||
|---|---|---|---|---|---|
| Present (n = 18) | Absent (n = 22) | Present (n = 18) | Absent (n = 22) | ||
| ESR (mm/hr) | >30 | 12 (66.7 %) | 5 (22.7 %) | 14 (77.8 %) | 3 (13.6 %) |
| ≤30 | 6 (33.3 %) | 17 (77.3 %) | 4 (22.2 %) | 19 (86.4 %) | |
| hsCRP (mg/l) | >3 | 12 (66.7 %) | 3 (13.6 %) | 13 (72.2 %) | 5 (22.7 %) |
| ≤3 | 6 (23.4 %) | 19 (86.4 %) | 5 (27.8 %) | 17 (77.3 %) | |
| NLR | >3.5 | 3 (16.7) | 2 (9 %) | 6 (33.3 %) | 12 (54.5 %) |
| ≤3.5 | 15 (83.3 %) | 20 (91 %) | 12 (66.7 %) | 10 (45.5 %) | |
| IL-1 (pg/ml) | >6.25 | 5 (27.8 %) | 6 (27.3 %) | 3 (16.7 %) | 2 (9 %) |
| ≤6.25 | 13 (72.2 %) | 16 (72.7 %) | 15 (83.3 %) | 20 (91 %) | |
| IL-6 (pg/ml) | >5 | 16 (88.8 %) | 4 (18.2 %) | 15 (83.3 %) | 5 (22.7 %) |
| ≤5 | 2 (11.1 %) | 18 (81.8 %) | 3 (16.6 %) | 17 (77.3 %) | |
| TNF-α (pg/ml) | >8 | 4 (22.2 %) | 10 (45.5 %) | 8 (44.4 %) | 12 (54.5 %) |
| ≤8 | 14 (77.8 %) | 12 (54.5 %) | 10 (55.6 %) | 10 (45.5 %) | |
| IL-18 (pg/ml) | >215 | 16 (88.8 %) | 2 (9.1 %) | 16 (88.8 %) | 3 (13.6 %) |
| ≤215 | 2 (11.1 %) | 20 (90.9 %) | 2 (11.2 %) | 19 (86.4 %) | |
Abbreviations: ESR-erythrocyte sedimentation rate; hsCRP- highly sensitive C reactive protein; IL-interleukin; NLR-neutrophil to lymphocyte ratio; TNF- tumor necrosis factor.